A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants Wi

• Status: RECRUITING
• Trial end date: 2032-03-29

Summary

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

• Phase: PHASE3

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Treatments: Cyclophosphamide; Doxorubicin; Prednisolone; Prednisone; Rituximab; Vincristine